A rare acute systemic infection caused by the inhalation of Bacillus anthracis spores (e.g. through infected animal products, bioterrorism) and characterized by an initial stage where patients present...
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation for inhalational anthrax is limited due to its extreme rarity, with fewer than 1 in 1,000,000 individuals affected. This scarcity has resulted in limited systematic clinical studies and a lack of comprehensive clinical features. Additionally, the condition's acute nature and potential overlap with other respiratory diseases complicate its characterization.
If you or a loved one is affected by inhalational anthrax, it is crucial to seek care from specialists experienced in infectious diseases, particularly those with expertise in anthrax. While there are no specific patient organizations identified for this condition, you can find general support and information through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, consider looking into clinical trials that may offer access to new treatments or therapies.
There are currently three active clinical trials investigating treatments for inhalational anthrax. One FDA-approved treatment is anthrax immune globulin (human), while L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages is designated and in development. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=inhalational%20anthrax.
Actionable guidance for navigating care for inhalational anthrax
If you or a loved one is affected by inhalational anthrax, it is crucial to seek care from specialists experienced in infectious diseases, particularly those with expertise in anthrax. While there are no specific patient organizations identified for this condition, you can find general support and information through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, consider looking into clinical trials that may offer access to new treatments or therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for inhalational anthrax is limited due to its extreme rarity, with fewer than 1 in 1,000,000 individuals affected. This scarcity has resulted in limited systematic clinical studies and a lack of comprehensive clinical features. Additionally, the condition's acute nature and potential overlap with other respiratory diseases complicate its characterization.
If you or a loved one is affected by inhalational anthrax, it is crucial to seek care from specialists experienced in infectious diseases, particularly those with expertise in anthrax. While there are no specific patient organizations identified for this condition, you can find general support and information through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, consider looking into clinical trials that may offer access to new treatments or therapies.
There are currently three active clinical trials investigating treatments for inhalational anthrax. One FDA-approved treatment is anthrax immune globulin (human), while L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages is designated and in development. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=inhalational%20anthrax.
Actionable guidance for navigating care for inhalational anthrax
If you or a loved one is affected by inhalational anthrax, it is crucial to seek care from specialists experienced in infectious diseases, particularly those with expertise in anthrax. While there are no specific patient organizations identified for this condition, you can find general support and information through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, consider looking into clinical trials that may offer access to new treatments or therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation for inhalational anthrax is limited due to its extreme rarity, with fewer than 1 in 1,000,000 individuals affected. This scarcity has resulted in limited systematic clinical studies and a lack of comprehensive clinical features. Additionally, the condition's acute nature and potential overlap with other respiratory diseases complicate its characterization.
If you or a loved one is affected by inhalational anthrax, it is crucial to seek care from specialists experienced in infectious diseases, particularly those with expertise in anthrax. While there are no specific patient organizations identified for this condition, you can find general support and information through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, consider looking into clinical trials that may offer access to new treatments or therapies.
There are currently three active clinical trials investigating treatments for inhalational anthrax. One FDA-approved treatment is anthrax immune globulin (human), while L-alanoyl-D-glutamate endopeptidase from Bacillus-infected bacteriophages is designated and in development. For more information on ongoing trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=inhalational%20anthrax.
Actionable guidance for navigating care for inhalational anthrax
If you or a loved one is affected by inhalational anthrax, it is crucial to seek care from specialists experienced in infectious diseases, particularly those with expertise in anthrax. While there are no specific patient organizations identified for this condition, you can find general support and information through resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov. Additionally, consider looking into clinical trials that may offer access to new treatments or therapies.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 7 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.